Dr. Bobby Lanier was the 98th president to the Tarrant County Medical Society. He is also Past President of the
Dr. Lanier and his wife Sandy and their two children arrived
After a pediatric internship at UTMB, Dr. Lanier served in the Air Force and
completed a Pediatric Residency at
Dr. Lanier founded Fort Worth Allergy and Asthma Associates in 1977 and continues in active practice at North Texas Institute for Clinical trials. He sustains a practice for the indigent and non-insured community and as medical director of Lanier Education and Research Network, a corporation devoted to educational technology and pharmaceutical research. Dr. Lanier founded the Society of Principal Investors, a professional society of physicians conducting FDA pharmaceutical trials. Since joining the medical society in 1977, Dr. Lanier has been involved intensely in communication efforts. A medical society committee assignment in 1980 led to his involvement locally with the NBC television affiliate where he served in a public service capacity from 1981-2001. He has appeared on “Ophra”, several times on “Nightline with Ted Koppell”, the “Today Show ”,”Nightly News with Tom Brohaw”, “Good Morning America”, “Good Morning South Africa” and “Radio Zulu”. Dr. Lanier founded the National Association of Physician Broadcasters. Dr. Lanier also served as an NBC television network correspondent from 1982-1985 after which time his television segments were internationally syndicated daily to over 100 television markets and heard in over 250 radio stations in this country and worldwide through the Armed Forces Radio and Television Network. Dr. Lanier founded the National Association of Physician Broadcasters. He was honored in 1995 by the American Medical Association with the Education and Research Foundations award for public communications.
Dr. Lanier stood for public office ( Congressional District 12) in 1989 and was defeated by Rep. Pete Geren . Dr. Lanier co-chaired the successful Congressional campaign of Representative Kay Granger.
Dr. Lanier is a passionate fisherman, photographer, and sports writer .His
articles and photographs have appeared in in-flight and sports
magazines. He has written over 400 articles on sports fishing for
magazines such as Saltwater Sportsman,
BOBBY QUENTIN LANIER, M.D.
· Post-graduate professional education:
(Pediatrics, 1971-1973) Certification, 1975
(Immunology 1973-1975) Certification, (1977)
· Certified Clinical Research Investigator: Association of Clinical Research Professionals (2002)
Certified Clinical Research Investigator:
Award, American Lung Association of
Bela Schick Lecture, American
· American Medical Association, Education and Research Foundation Award
For Health Education (1994)
· Heart Association Paul R. Ellis Media Award (1990, 1994, 1998)
Best Documentary “Cancer:
· Achievement of Excellence, documentary “Cancer: Texas Strikes Back”
(1980, 1981, 1982, 1983, 1984, 1985, 1986)
Clinical Professor of Pediatrics: University of
· Editorial Board Proceedings of Allergy Asthma and Immunology (2004 – present)
· Editor – John Hopkins, Asthma Monitor (2001-2002)
· Medical Director- North Texas Institute for Clinical Trials: (1982-present)
· Founder and Executive Director- Medical Media Network: (1982-present)
· Private Practice- (1977- 1999)
· Chief / training director - Ped Allergy/Immunology, Wilford Hall USAF
· Board of Directors, World Allergy Organization (2005- present)
· President – Association of Certified Allergists (2002-2003)
· Founder/EVP: Society of Principal Investigators (2000 – present)
· Board of Directors; Texas Medical Association Foundation (1998-present)
· Chairman: AllerDays Research Council for HMR (1997-1999)
Chairman: Managed Care Council:
and Immunology (1995-1996)
Founder and Executive Director:
Communicators (1990- present)
· Delegate (alt) American Medical Association American College of Allergy Asthma
and Immunology (1990-present)
· Board of Directors: Joint Council of Allergy and Immunology (1990-1995)
· Senior Vice President Harris Methodist Health System, Communications
Research (1989- 1998)
· Anchor / Editor: Medical Economics Video Magazine (1989 - 1995)
Board of Regents, Executive Committee,
Immunology (1989- 1995)
· Chairman: International Allergy Group for Scherring Corporation (1989-1993)
· President, National Association of Physician Broadcasters (1989-1991)
· Nominee for Congress, District 12 (1989)
Chairman, Joint Marketing Task Force,
· Chairman, Public Education Task Force on Cancer (1987)
· Founder, National Association of Physician Broadcasters (1986-1991)
· Medical Consultant, NBC News (1984-1986)
Chairman, Council on Communications,
Medical Director, North Texas Institute for Clinical Trials,
· Founder/CEO - Bob Lanier, MultiMedia - (1982 - present) A medical communications and video corporation
· Medical Consultant, KXAS TV, (NBC) (1981 - 1998)
· World Allergy Organization (2001 – present)
Alternate Delegate (
American Medical Assoc., (1991- present)
· Society of Professional Journalists (1988-present)
· Radio & Television News Directors Association (1987-present)
· Board of Directors, American Lung Association (1984-1985)
· American Medical Association (1979-present)
· Texas Medical Association (1979-present)
· Tarrant County Pediatric Society (1979-present)
Board of Directors,
Board of Directors,
· American Association of Certified Allergists (1977-present)
· Diplomat, American Board of Pediatrics (1975-present)
· Phi Beta Phi Medical Fraternity (1966-present)
Clinical Professor of Pediatrics: University of
· Faculty: Pilot program Scientific Communications fellowship World Allergy Organization (2006)
Assistant Clinical Professor, Department of Medicine
· Faculty, American Medical Association - Annual Health Reporting
Supervisor: Clerkships for Family Practice Residents,
Director Allergy division:
Department of Family Practice,
Attending physician: Division of
Internal Medicine and Family Practice,
· Advisory Board of Directors, Samaritan Housing for AIDS (1997-present)
Advisory Board, Tarrant
Advisory Board of Directors,
· Advisory Board Member, American Institute for Teen AIDS Prevention (1990-present)
· Spokesperson, Kid Care - Volunteer Connection, KXAS-TV (1990-1998)
Finance and Executive Board, First United
· Board of Directors: Women with Aids (a childcare facility for the children of
families with AIDS) (1988)
Board of Directors:
Medical Facility) (1984-1998)
· Board of Directors, Salvation Army (1983-1987)
Founder, Asthma Camp for Children, "
· Board of Directors, Citizens Advisory Council for Cable Television (1981-1983)
· Board of Directors, Camp Carter-YMCA (1981-1983)
· Oprah, 1999, “Surviving a Hospital Stay”
· Talent: Schering Cable television half hour : Allergies - fact and myth ( 1995)
· Talent: Schering Cable television half hour: Allergies- how to survive (1995)
· Talent: "Medical Talk Etc..." KCBI Radio - weekly medical talk show (1991- 1993)
· Medical reporter - KCBI Radio (1990-present)
· Anchor: Medical Economics Video Magazine, a quarterly broadcast
and tape (1989-1995)
· Medical commentator - WBAP Radio (1985-2001)
· Talent, Writer, Producer: Sixty Second Housecall, daily national radio/television commentary in syndication (1985- 2001)
· Nightline Guest (ABC), Jan. 1985, "The Fate of Private Practice".
· Medical Reporter, KXAS TV, (NBC) (1981 - Present)
· NBC "A" News correspondent (1984-1986)
· Medical commentator - "Master Control", Southern Baptist Radio/TV
· Nightline Guest (ABC), July 1984, "Controversies in Allergy".
· Medical commentator: Medical Portfolio - an audio cassette journal (1983-present)
· Talent, producer, writer: Glaxo- “Overview of Allergy (Introductory videotape)
· Talent, writer, producer: Glaxo- “Overview of Asthma (Introductory videotape)
· Talent, writer, producer: “Good news about heart attack treatment” 30 minute
broadcast documentary (1990)
· Textbook Chapter, Anti-IgE “Atlas of Allergy” Blaiss, Liberman 2005
· The Physician as Communicator - a text of communication skills for physicians.
· The New Epidemic: A Patient Survival Guide to Asthma (in progress)
· CD-ROM: Interactive Cases in Asthma (1995)
· CD-i Interactive Asthma Education Series
(J Asthma, 1999 Dec)
---------------------------------------------- non cited -------------------------------------
· AstraZeneca D5360C00703 – Study to Assess the Safety and Efficacy of Rhinocort Aqua in patients 2-5 with AR
· Criterium MGP707- A Multi-center, Three Arm, Parallel group, Double-blind Placebo-controlled, randomized study of Bioequivalence and Efficacy of Fluticasone Propionate Nasal Spray Compared to Flonase Nasal Spray In Patients with Seasonal Allergic Rhinitis
· Schering PO4095 – Efficacy and Safety of Combination Loraradine/Monelukast QD vs Pseudoephedrine and Placebo in the Treatment of Subjects with Seasonal Allergic rhinitis
· Alcon C-03-49 – Olopatadine VRS Astelin in patients with allergic rhinitis
· Symbio CPL-404 – Triamcinolone Acetonide Nasal Spray compared with Nasacort AQ
· Alcon C-04-20 – Peds Study, Olopatadine Hydrochloride Nasal Spray versus Placebo
· Altana Pharma BY90101/M1-403 - Study to Assess the Safety and Efficacy of Ciclesonide Nasal Spray vs. Placebo in Children 6 - 11 with PAR.
· ALTANA Pharma BY217/M2-023 – Roflumilast versus Placebo
· AstraZeneca D5896C0005 – Symbicort versus Advair
· Alcon C-01-92 – Long Term Safety Study of Olopatadine Nasal Spray
· AstraZeneca SD-004-0764 – Comparing the Efficacy and Safety of Pulmicort Respules at different dosages and the Pulmicort Turbuhaler in patients ages 12 years and older with moderate to severe asthma.
· AstraZeneca SD-004-0726 – Comparison of Pulmicort Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Children and Adolescents.
· ALTANA Pharma BY9010/M1-402 – Study to Assess the Safety and Efficacy of Ciclesonide Nasal Spray vs. Placebo in Patients 12 and Older with PAR.
· Dey D1-055 – Pediatric Study comparing Formoterol Fumarate Inhalation Solution and Formoterol Dry Powder Inhaler; placebo controlled.
· Sepracor 051-354 – An Efficacy, Safety, and Tolerability Study of daily dosing with Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects (4-11 years) with Asthma.
· Aventis MO16455P/3001- Study to assess the efficacy and safety of Fexofenadine with subjects with mild to moderate persistent asthma.
· Aventis MO16455P/3003 – Study to assess the long-term safety performance of Fexofenadine compared to Montelukast.
· Aventis XRG5029C/4007 – Comparing the Efficacy of Nasacort AZ with Rhinocort for the Treatment of Seasonal Allergic Rhinitis Symptoms in patients 12-65 years of age.
· Novartis CFOR258D2307 – Evaluating safety and efficacy of treatment with 24 mcg bid and 12 mcg bid formoterol, and 12 mcg bid formoterol with additional on-demand doses in adolescent and adult patients with persistent stable asthma.
· Astra Zeneca SD-039-0718 – Symbicort versus its Mono-Products (budesonide and formoterol) in Asthmatic Children Aged 6 – 15 yrs.
· Astra Zeneca SD-004-0620 – Comparison of Pulmicort Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Adults
· Sepracor 051-353 – Efficacy and Safety Study of Levalbuterol, Racemic Albuterol in subjects 12 years and older.
· Aventis XRP1526B-341 – Ciclesonide Metered Dose Inhaler in the treatment of children with persistent asthma.
· GlaxoSmithKline SAS40036 – Comparison of Asthma Control in adolescents and adults receiving either Fluticasone Propionate/Salmeterol Diskus combination product, Fluticasone Propionate Diskus, Salmeterol Xinafoate Diskus, or Oral Montelukast.
· Aventis HMR3647A/3014 – Oral Telithromycin and Amoxicillin/Clavulanic Acid in outpatients with respiratory tract infections in usual care settings.
· Novartis FOR258F0604 – Evaluating the safety, efficacy, and pharmacokinetics of Foradil versus placebo.
· Sepracor 110-073 – A Double-Blind, Placebo and Active-Controlled, Parallel Group Study of Tecastemezole.
· Schering-Plough PO1861 – A Placebo and Active Controlled Efficacy and Safety Study of Desloratadine/Pseudoephedrine.
· Genentech, Inc. Q2461g – An open-label study II of of Omalizumab in moderate to severe, persistent asthma subjects.
· Genentech, Inc. Q2195g – An open-label extension study of Omalizumab in moderate to severe, persistent asthma subjects.
· Genentech, Inc. Q2143g – An open label study to evaluate the safety of Omalizumab in moderate to severe, persistent asthma subjects.
· Schering S83-022 - A Comparison of Two Major Treatment Modalities in the Therapy of Exercise Induced Asthma
· Schering S85-035 - A Study of the Safety and Efficacy of Loratadine Plus Pseudoephedrine Compared with Placebo in Patients with Seasonal Allergic Rhinitis
· Schering S87-001 SCH 434 - Loratadine Plus Pseudoephedrine) Versus Tavist-D in Seasonal Allergic Rhinitis
· Warner-Lambert/Parke-Davis 184-56 - A Two-Week, Multicenter, Double-Blind, Dose-Ranging Study of the Comparative Efficacy and Safety of Low Dose Sustained Release Benadryl, Standard-Release Benadryl, and Placebo in Outpatients with Allergic Rhinitis
· Schering S88-001 - Once Daily Claritin vs. Benadryl, Three Times Daily, Verses Placebo
· Schering S88-047-03 - Loratadine Tablets vs Loratadine Capsules vs Placebo in Seasonal Allergic Rhinitis
· Schering-Plough C91-105-103 - A Patient Preference Study of Vanceril MDI vs Azmacort MDI
· Parke-Davis 888-201 - A Multicenter Double-Blind Three Month Study of the Comparative Efficacy and Safety of Procaterol and Albuterol Aerosol Administered QID in Outpatients with Reversible Bronchial Airway Obstruction
· Rhone-Poulenc Rorer 5016-117 - A Cohort Epidemiologic Study to Determine the Effect of One Year of Azmacort (Triamcinolone Acetonide) or Alternate Day Prednisone or Alternate Day Prednisone Plus Azmacort or Nonsteroidal Antiasthmatic Therapy on Growth Patterns of Asthmatic Children
· Glaxo FLI-302 - A Randomized Double-Blind Comparative Trial of Inhaled Fluticasone Propionate Versus Theophylline Verses Placebo in Adolescent and Adult Patients with Mild to Moderate Asthma
· Carter Wallace 368 – A Randomized, Double-Blind Study of Astelin Nasal Spray versus Combination Therapy Nasal Steroid and Oral Antihistamines in Subjects with Seasonal Allergic Rhinitis.
· Aventis MO16455C/3212 - A Double-blind, Randomized, Placebo-controlled, Parallel Group Study Assessing the Efficacy and Safety of Fexofenadine in Pediatric Subjects.
· Aventis MO16455I/3112 – A Multicenter, Double-Blind, Randomized, Placebo-controlled. Parallel Study to Assess the Safety and Tolerability of Fexofenadinein Children ages 2 through 5.
· Aventis MO16455I/3112B– A Multicenter, Double-Blind, Randomized, Placebo-controlled. Parallel Study to Assess the Safety and Tolerability of Fexofenadinein Children ages 2 through 5.
· Aventis MO16455P/2113 – A Multi-center, Doulbe-Blind, Randomized, Parallel Groups Placebo-controlled Pilot Study to Observe the Effects of Montelukast in combination with Fexofenadine on Persistent Mild to Moderate Asthma Subjects.
· Glaxo Wellcome FDP40012- A Randomized, Double-Blind, Double Dummy, Parallel Group Comparison of Fluticasone Inhalation Powder via Diskus with Oral Montelukast Chewable Tablets in Children ages 6-12 with Persistent Asthma.
· GlaxoSmithKline SAM40027 – A Multicenter, Stratified, Randomized, Double-Blind, Parallel Group, Step-up Comparison of the Level of Asthma Control Achieved with Salmeterol/Fluticasone Combination Diskus compared with Fluticasone Diskus Alone in Adults and Adolescents.
· Glaxo Wellcome SAS40026 – A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Combination Diskus Versus Fluticasone inhaler in Adolescents and Adults with Moderate Persistent Asthma
· Glaxo Wellcome SAS40021 – A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12 Week Comparative Trial of Salmeteral/Fluticasone Combination Diskus Versus Oral Montelukast in Adolescents and Adults with Persistent Asthma.
· Glaxo Wellcome FMS30058 – A Multicenter, Randomized, Doulbe-Blind, Parallel group, Placebo-controlled, 12 –week Study of Fluticasone Propionate Delivered CFC MDI and a Valved Holding Chamber with Facemask in Subjects Age 24 Months to 47 Months with Asthma.
· Glaxo Wellcome FMS30059 - A Multicenter, Randomized, Doulbe-Blind, Parallel group, Placebo-controlled, 12 –week Study of Fluticasone Propionate Delivered CFC MDI and a Valved Holding Chamber with Facemask in Subjects Age 6 Months to 23 Months with Asthma.
· Immunex 13.0019 – Phase II Efficacy Study of Nebulized Recombination Human IL-4 Receptor in Asthma Patients using Inhaled Corticosteriods.
· Millennium M97700-023 – A Phase II, Randomized, Placebo-controlled, Double-Blind, Parallel group Dose-Finding Study to Evaluate the Effectiveness of Treatment with LDP-977 in Adult Asthmatics.
· Amyllin 137-122 - A Double-Blind, Placebo-controlled, Multicenter, Phase III Study to Evaluate the Effects of Pramlintide in Patients with Type II Diabetes Mellitus.
· Alcon C-99-37 – A Randomized, Controlled Study to Evaluate the Safety and Efficacy of Topical Cipro Compared to Cortisporin for treatment of Acute Otis Externa.
· Alcon C-00-33 – A Placebo-controlled, Environmental Study of Patanol Nasal Spray versus Astelin Nasal Spray in Subjects with Seasonal Allergic Rhinitis.
· 3M 1343-BRON – A 12-week Comparison of Daily Dose of Beclomethesone Dipropionate versus Placebo in Autohaler Device in Pediatric Patients with Symptomatic Asthma.
· 3M 1332-SILV – Safety and Efficacy Study of Albuterol Sulfate Delivered from a Press and Breath MDI, the Autohaler and Placebo in Patients with Asthma.
· Sepracor 091-004 – A Safety, Efficacy and Tolerability Study of Multiple Once-Daily Doses of Fometerol Inhalation Solution in Subjects with Asthma.
· Schering Plough PO1998-21- Efficacy and Safety of Combination Loratadine/Monelukast versus Its Components in the Treatment of Subjects Seasonal Allergic Rhinitis.
· Schering Plough PO1545-16 – Placebo-controlled Efficacy and Safety Study of a Once- Daily and Twice-Daily Regimens of Mometasone Furoate via Dry Powder Inhaler in Subjects with Asthma Previously Maintained on Inhaled Corticosteroids.
· Schering Plough PO00687-09 – Efficacy and Safety of SCH29851 in Subjects with Seasonal Allergic Rhinitis.
· Schering Plough PO0216-27 – Efficacy and Safety of SCH34117 in Patients with Seasonal Allergic Rhinitis and Concurrent Asthma.
· Rhone-Poulenc Rorer RG5016Y-204 – A Phase II/III Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Efficacy, Safety and Dose Response Study of Azmacort Inhalation Aerosol in treatment of Mild and Moderate Persistent Asthma in Adolescents and Adults.
· Pfizer A3771001 – A Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study of the Efficacy and Safety of Cetrizine-Pseudoephedrine versus Loratadine-Pseutophedrine versus Placebo in the Treatment of Subjects 12 and Older with Seasonal Allergic Rhinitis.
· G.H. Besselaar Associates GHBA-168 - (Astra Draco 04-3022) A Double-Blind, Randomized, Placebo-Controlled Study to Determine the Efficacy and Safety of Three Different Doses of Pulmicort (Budesonide) Turbuhaler in Pediatric
Patients with Glucocorticosteroid Treated Asthma
· Glaxo SLGA 5003 - A Randomized, Double-Blind, Parallel Group Evaluation of the
Safety, Efficacy, and Effect on Asthma Quality of Life of Salmeterol Versus
Nebulizing Suspension and Placebo in Asthmatic Children Aged Between Four
and Eight Years
· Merck MK-0476 - A Multicenter, Double-Blind, Randomized, Parallel-Group Study Comparing the Clinical Effect of Three Oral Doses of MK-0476 and Placebo in Adult
Patients with Stable, Moderate Asthma
· Rhone-Poulenc Rorer RG-5016T-203 - A Double-Blind, Dose-Ranging Study of
Azmacort HFA-134a Oral Inhaler Compared to Azmacort Oral Inhaler in the
Treatment of Asthma in Children
· Glaxo SLGA5017 - A Comparison of Adding Serevent Versus Doubling the
Dose of Beclovent in Asthmatic Subjects Symptomatic on Their Existing
· Glaxo FLTA2008 - A Randomized, Double-Blind, Parallel-Group Trial Assessing the
Efficacy and Safety of Fluticasone Propionate via the Multi-Dose Powder
Inhaler 100MCG BID, 200 MCG QD, and Placebo in Subjects Aged 4 to 11
Years with Chronic Asthma
· SmithKline Beecham Pharmaceuticals SB 205312/012 -A Multi-Center,
Double-Blind, Placebo-Controlled, Parallel Group Comparison of the Safety
and Efficacy of Oral Twice Daily Administration of SB 205312 with Inhaled
Tilade in Patients with Mild to Moderate Asthma
· Rhone-Poulenc Rorer RG5029Y A Randomized, Placebo-controlled, Parallel Group,
Multiple-Dose Study of RG5029Y on Hypothalamic-Pituitary-Adrenal (HPA)
Function and Pharmacokinetic Profile in Pediatric Patients with Allergic Rhinitis
· SmithKline Beecham Pharmaceuticals SB 205312-084 A Multi-Center,
Double-Blind, Placebo-Controlled, Parallel Group Study of Evaluate the Safety
and Efficacy of Oral Twice Daily Administration of SB 205312 in Pediatric Patients
with Mild to Moderate Asthma
· SmithKline Beecham Pharmaceuticals SB 205312-087 A Multi-Center, Open Label, Long Term Study of the Safety, Tolerability and Efficacy of Oral SB 205312 in Pediatric Patients with Mild to Moderate Asthma
· Glaxo Wellcome FLTA4015 A Randomized, Double-Blind, Parallel-Group, Comparative Trial of inhaled Fluticasone Propionate (84 mcg and 336 mcg BID) Via the Metered-Dose Inhaler in Asthmatic Subjects Previously Treated with Beclomethasone Dipropionate
· Hoechst Marion Roussel PJPR0053 A Double-Blind, Randomized Study Comparing the Efficacy and Safety of Fexafenadine and Placebo in Black Patients with Seasonal Allergic Rhinitis
· TAP Pharmaceuticals M94-216 Safety and Efficacy of AA-2414 (ABT-001) in Patients with Moderate Asthma
· SmithKline Beecham Pharmaceuticals SB 205312-080 A double-blind, double dummy, placebo-controlled, randomized, parallel group study to examine the effects of oral SB 205312 mg BID in patients with asthma and concomitant seasonal allergic rhinitis - a comparison to patients taking inhaled Vanceril 168 mcg BID and as required nasal rescue medication
· Sepracor 051-024 A Phase III Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study of the effects of (R)-Albuterol in the Reversal of Bronchoconstriction and in the Management of Asthma
· SmithKline Beecham Pharmaceuticals SB 205312-07 A Multicenter, Double-blind, Placebo-Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Two Doses Of SB 205312 Administered As An Oral Suspension (75 MG BID And 150 MB BID) for 12 Weeks In Pediatric Out-Patients With Asthma
· Glaxo Wellcome SLGA 5021 A Randomized, Double-blind Clinical Trial Comparing The Efficacy And Safety Of Salmeterol Xinafoate 42 MCG BID Plus Fluticasone Propionate 88 MCG BID Alone In Subjects with Asthma Not Well controlled On Fluticasone Propionate 88 MCG BID
· Ciba-Geigy Corporation 51901 01 04 A Double-blind, Randomized, Parallel-Group, placebo-Controlled, Multiple-Dose (Intravenous Infusions of 35 MG, 58 MG, or 93 MG CGP 51901 Q 2 Weeks x 6) Multicenter Pilot Trial To Assess The Efficacy, Safety, Tolerability, Pharmacokinetics, And Biologic Activity of CGP 51901 In Patients 18-40 Years Old With Mild To Moderate Perennial Allergic Asthma
· GlaxoWellcome FLTA 4025 A Randomized, Double-Blind, Placebo-controlled Study Examining The Effect Of Fluticasone Propionate Aqueous Nasal Spray 200 MCG QD Used In Conjunction With An Antibiotic In Allergic Subjects With Recurrent Sinusitis
· Novartis 049 A Twelve-month, Double-Blind, Between-Patient, Placebo-Controlled Trial Comparing the Safety, Tolerability and Efficacy of 12 ug and 24 ug and 24 ug Twice Daily Formoterol Dry Powder Capsules for Inhalation Delivered by a Single-Dose Inhaler (Aerolizer) in Children With Asthma in Need of Daily Treatment with Inhaled Bronchodilators and Anti-Inflammatory Treatment
· Glaxo SFCA 3003 A Randomized, Double-Blind Trial Evaluating safety and Efficacy of Salmeterol 50 mcg BID and Fluticasone Propionate 250mcg BID Individually and in Combination and Placebo in Patients with Asthma
· Abbott M96-464 Long Term Safety Study of Zileuton Controlled-Release Plus Usual Care Versus Placebo Plus Usual Care in Patients with Asthma
· Novartis Pharmaceuticals rhuMAb-E25 01 006 - A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose (Subcutaneous Administrations of 50 mg, 150, mg or 300 mg), Multicenter, Dose-Ranging Trial To Assess The Efficacy, Safety, Tolerability, Pharmacokinetics And Biological Effect Of Anti-Ige Recombinant Humanized Monoclonal Antibody-E25 (rhuMAb-E25) Versus Placebo For Symptoms Effect Of Anti IgE Recombinant Humanized Monclonal Antibody-E-25 (rhuMAb-E25) Versus Placebo For Symptom Prevention In Patients With Ragweed Induced Seasonal Allergic Rhinitis”
· Astra Merck 153 - Comparison of the Safety and Antihypertensive Efficacy of the Fixed Combination of Candesartan Cilexetil and Hydrochlorothiazide (32/12.5 mg) Once Daily with the Individual Components Administered Once Daily: A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Design Study
· Pfizer L-0350, An open Label, Multicenter Study of the Efficacy, Safety, and effect on Quality of Life of Zyrtec® (certirizine HCL) Syrup in the Treatment of Seasonal Allergic Rhinitis in Children
· Hoechst Marion Roussel MO16455B / 3081 - A Double-blind Randomized, Placebo-Controlled Parallel Study comparing the Efficacy and Safety of Fexofenadine HC1 120 mg And 180 mg QD In The Treatment Of Autumn Seasonal Allergic Rhinitis
· Schering-PloughC97- 223-16 - Placebo-Controlled Efficacy and Safety Study with Long-Term Safety Evaluation of Mometasone Furoate HFA-227 Metered Dose Inhaler in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Beta-Agonists
· GlaxoWellcome FLTA 4030 - A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Comparative Study of Inhaled Fluticasone Propionate (88 mcg BID) Versus Zafirlukast (20mcg BID), in Subjects Who are Currently Receiving Beta Agonista Alone
· Astra Merck 175 - Evaluation of the Antihypertensive Effect of Candesartan Cilexetil
in Comparison to Losartan
· ViroPharma 843-013 - A Double-Blind, Placebo Controlled Exploratory Evaluation
of Pleconaril (VP-63843) in the Treatment of Rhinovirus Upper Respiratory Tract
Infections in Patients with Moderately Severe Bronchial Asthma
· GlaxoWellcome FLTA 4035 - A Randomized, Double-Blind, Double-Dummy, Parallel Group, Comparative Study of Inhaled Fluticasone Propionate 88 Mcg BID Versus Zafirlukast 20 Mg BID in Asthmatic Subjects Who Are Currently Receiving Low Dose Inhaled Corticosteroids
· Novartis Pharmaceuticals rhuMAb-E25 01 008 - A Phase III, 7 Month, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial With a 5-Month Blinded Extension Period To Assess the Efficacy, Safety, Tolerability, Steroid-Reduction, Pharmacokinetics, and Pharmacodynamics of Subcutaneous rhuMAb-E25 in Adolescents and Adults With Moderate To Severe Allergic Asthma Requiring Daily Treatment With Inhaled Corticosteroids
· Wallace 368 - A Randomized, Double-Blind Study of Astelin® Nasal Spray Monotherapy Versus Combination Therapy of A Nasal Steroid and Oral Antihistamine in Subjects With Seasonal Allergic Rhinitis
· Astra Merck Inc. 183 - A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Omeprazole, 10 mg QD,
in Preventing Heartburn
· Novartis Pharmaceuticals rhuMAb-E25 01 010 - A Phase III, 7 Month, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial With a 5-Month Open-Label Extension Period To Assess Safety and Tolerability, Steroid-Reduction, Pharmac cokinetics, and Pharmacodynamics of Subcutaneous rhuMAb-E25 in Children (6-12 years) With Allergic Asthma Requiring Daily Treatment With Inhaled Corticosteroids
· Novartis Pharmaceuticals rhuMAb-E25 01 010 Extension- A Phase III, 7 Month, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial With a 5-Month Open-Label Extension Period To Assess Safety and Tolerability, Steroid-Reduction, Pharmac cokinetics, and Pharmacodynamics of Subcutaneous rhuMAb-E25 in Children (6-12 years) With Allergic Asthma Requiring Daily Treatment With Inhaled Corticosteroids
· Alcon C98-19 - Topical CILODEX™ (ciprofloxacin 0.3%, dexamethasone 0.1%) Suspension Compared to CORTISPORIN® Suspension (neomycin 0.35%, ploymyxin, 10,000 IU mL, Hydrocortisone 1.0%) for Treatment of Patients with Acute Otitis Externa (AOE)
· Alcon C98-04 - An Observer-Masked Adjunctive Therapy Environmental Study of Patanol With Claritin Versus Claritin Alone in Patients With Seasonal Allergic Conjunctivitis
· Rhone-Poulenc Rorer 5016Y-204 - A Phase II/III Double Blind Placebo-Controlled, Parallel-Group, Multicenter Efficacy, Safety and Dose Response Study of Azmacort (triamcinolone acetonide) HFA-134a Inhalation Aerosol 225 mcg, 450 mcg and
900 mcg Administered Once Daily for 12 weeks in the Treatment of Mild Persistent
and Moderate Persistent Asthma in 800 Adolescents and Adults
· Novartis 009 - A Phase III, 7-Month, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Trial with a 5-Month Blinded Extension Period to Assess The Efficacy, Safety, Tolerability, Steroid-Reduction, Pharmacokinetics of Subcutaneous rhu-MAB-E25 in Adolescents and Adults With Moderate to Severe Allergic Asthma Requiring Daily Treatment With Inhaled Corticosteroids.
· Pfizer 362 - A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of the Efficacy, Safety, and Effect on Quality of Live, Work Productivity and Activity Impairment of Zyrtec vs. (Cetirizine HCI) vs. Placebo in the Treatment of Seasonal Allergic Rhinitis
· FLTA 4038 - A Randomized, Double-Blind, Parallel Group Comparison Study of Inhaled Fluticasone Propionate (88mcg BID) Versus Montelukast Sodium (10mg QD) in Subjects Currently Receiving Beta Agonists Alone
· GlaxoWellcome 40004 - A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Salmeterol Xinafoate Inhalation Powder (50mcg BID) With Oral Montelukast (10mg QD) In Subjects With Persistent Asthma Symptomatic on Concomitant Inhaled Corticosteroid Therapy
· GlaxoWellcome 30004 - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety and Efficacy of Salmeterol/Fluticasone Propionate Combination in GR106642X MDI, 50/250mcg BID, and Salmeterol in Propellant 11/12MDI, 50mcg BID, and Fluticasone Propionate in Propellant 11/12MDI, 250mcg BID, and Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma
· Novartis CIGE025AUS23- A 26-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center, Study to Evaluate the Effect of Xolair (Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients with Persistent Allergic Asthma
· Alcon C-05-69: 12 month safety study of Olopatadine Nasal Spray
· Schering Plough P04824-efficacy/safety of MFNS vs placebo as adjunctive treatment to antibiotics in relief of symptoms of acute bacterial sinusitis
· Sanofi Aventis EFC6695-efficacy/safety of ciclesonide metered-dose inhaler at 80 mcg BID vs 40 mcg BID vs placebo in children 4 to 11 yrs
· Sanofi Aventis XRG5029C/3503-12 month effect of treatment with QD triamcinolone acetonide on growth velocity of children 3-8 yrs with SAR
· Amgen Inc. AMG317-safety/efficacy of AMG317 in subjects with moderate to severe asthma
Genentech Q3663g – A
· Novartis IGE025A US23-Omalizumab efficacy on improving tolerability of specific immunotherapy in patients with persistent allergic asthma
· Genentech Q2948g – An Epidemiologic study of Xolair Evaluating Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma
· Novatris CIGE025AIA05 – An Evaluation of Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Omalzumab in Children 6-12 with Moderate-Severe Persistent Asthma